In 'real-life', the Nordic score guides Erythropoietic stimulating agent (ESA) use in lower-risk myelodysplastic syndrome (MDS) with predicted response rates of 25% or 74%. As new treatments emerge, a more discriminating score is needed.
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems / Buckstein, R., Balleari, E., Wells, R., Santini, V., Sanna, A., Salvetti, C., Crisà, E., Allione, B., Danise, P., Finelli, C., Clavio, M., Poloni, A., Salvi, F., Cilloni, D., Oliva, E.N., Musto, P., Houston, B., Zhu, N., Geddes, M., Leitch, H., et al.. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 1096-8652. - ELETTRONICO. - 92:(2017), pp. 1037-1046. [10.1002/ajh.24842]
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems
Santini, Valeria;Sanna, Alessandro;
2017
Abstract
In 'real-life', the Nordic score guides Erythropoietic stimulating agent (ESA) use in lower-risk myelodysplastic syndrome (MDS) with predicted response rates of 25% or 74%. As new treatments emerge, a more discriminating score is needed.
| File | Dimensione | Formato | |
|---|---|---|---|
|
301.html
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
22.77 kB
Formato
HTML
|
22.77 kB | HTML | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
